Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of HER-2 (green) showing staining in the membrane of SK-BR-3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a HER-2 monoclonal antibody (Product # MA5-12998) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a flourescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
|Tested species reactivity||Human|
|Published species reactivity||Hamster, Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Intact SKBR-3 breast cancer cells|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:200|
|Immunomicroscopy (IM)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunoprecipitation (IP)||See 3 publications below|
|Immunocytochemistry (ICC)||See 5 publications below|
|Flow Cytometry (Flow)||See 1 publications below|
|Immunohistochemistry (IHC)||See 1 publications below|
|Western Blot (WB)||See 1 publications below|
|ELISA (ELISA)||See 1 publications below|
MA5-12995 targets HER-2 in ICC/IF, IHC (F), IHC (P) and IM applications and shows reactivity with Human samples.
The MA5-12995 immunogen is intact SKBR-3 breast cancer cells.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
MA5-12995 was used in immunoprecipitation to investigate the state of HER1-HER2 interaction and modification in cell lines and tumors
|DeFazio-Eli L,Strommen K,Dao-Pick T,Parry G,Goodman L,Winslow J||Breast cancer research : BCR (13:null)||2011|
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
MA5-12995 was used in immunoprecipitation to investigate the effect of lapatinib on cell proliferation regulated by EGFR/HER2
|Gilmer TM,Cable L,Alligood K,Rusnak D,Spehar G,Gallagher KT,Woldu E,Carter HL,Truesdale AT,Shewchuk L,Wood ER||Cancer research (68:571)||2008|
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
MA5-12995 was used in immunoprecipitation and western blot to study the mechanisms underlying the regulation of truncated ErbB2 receptor by heregulin
|Xia W,Liu LH,Ho P,Spector NL||Oncogene (23:646)||2004|
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
MA5-12995 was used in immunocytochemistry, immunoprecipitation, and western blot to study the role of truncated nuclear ErbB2 in acquired resistance to ErbB2 kinase inhibitors in tumor cells
|Xia W,Liu Z,Zong R,Liu L,Zhao S,Bacus SS,Mao Y,He J,Wulfkuhle JD,Petricoin EF,Osada T,Yang XY,Hartman ZC,Clay TM,Blackwell KL,Lyerly HK,Spector NL||Molecular cancer therapeutics (10:1367)||2011|
Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy.
MA5-12995 was used in immunocytochemistry to study silica-gold nanoshells as potential probes for HER2-overexpression in ex vivo breast tissue
|Bickford LR,Agollah G,Drezek R,Yu TK||Breast cancer research and treatment (120:547)||2010|
Enhanced multi-spectral imaging of live breast cancer cells using immunotargeted gold nanoshells and two-photon excitation microscopy.
MA5-12995 was used in immunocytochemistry to develop a method for multi-spectral imaging of live breast cancer cells using immunotargeted gold nanoshells
|Bickford L,Sun J,Fu K,Lewinski N,Nammalvar V,Chang J,Drezek R||Nanotechnology (19:null)||2008|
Immunonanoshells for targeted photothermal ablation of tumor cells.
MA5-12995 was used in immunocytochemistry to study the use of immunonanoshells for targeted photothermal ablation of tumor cells
|Lowery AR,Gobin AM,Day ES,Halas NJ,West JL||International journal of nanomedicine (1:149)||2007|
Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.
MA5-12995 was used in immunocytochemistry to examine the mechanism for the lapatinib sensitivity in breast cancer cell lines
|Hegde PS,Rusnak D,Bertiaux M,Alligood K,Strum J,Gagnon R,Gilmer TM||Molecular cancer therapeutics (6:1629)||2007|
Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.
MA5-12995 was used in flow cytometry to validate a method for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens
|Larson JS,Goodman LJ,Tan Y,Defazio-Eli L,Paquet AC,Cook JW,Rivera A,Frankson K,Bose J,Chen L,Cheung J,Shi Y,Irwin S,Kiss LD,Huang W,Utter S,Sherwood T,Bates M,Weidler J,Parry G,Winslow J,Petropoulos CJ,Whitcomb JM||Pathology research international (2010:null)||2010|
Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients.
MA5-12995 was used in immunohistochemistry to study the predictive value of tumor cell expression of HLA-DM in breast carcinoma patients
|Oldford SA,Robb JD,Codner D,Gadag V,Watson PH,Drover S||International immunology (18:1591)||2006|
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
MA5-12995 was used in western blot to develop and characterize specific antibodies targeting EGFR family
|Horak E,Heitner T,Robinson MK,Simmons HH,Garrison J,Russeva M,Furmanova P,Lou J,Zhou Y,Yuan QA,Weiner LM,Adams GP,Marks JD||Cancer biotherapy & radiopharmaceuticals (20:603)||2005|
C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment.
MA5-12995 was used in ELISA to investigate the prognostic value of C-erbB2 oncoprotein in Herceptin treatment
|Wu JT||Clinica chimica acta; international journal of clinical chemistry (322:11)||2002|
c-erb B2/neu protein; CD340; herstatin; human epidermal growth factor receptor 2; metas; metastatic lymph node gene 19 protein; MLN 19; MLN19; NEU; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; proto-oncogene c-ErbB-2; proto-oncogene Neu; tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
CD340; ERBB2; HER-2; HER-2/neu; HER2; MLN 19; MLN19; NEU; NGL; TKR1